^
    Apply
    Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT05757492)
    Phase 1/2
    Coherus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2024
    Initiation :
    04/26/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • PD-L1 • ALK • MET • ROS1
    |
    EGFR mutation • ALK mutation • MET mutation • ROS1 mutation
    |
    Loqtorzi (toripalimab-tpzi) • JS006